• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat Earnings

    4/3/24 2:30:25 PM ET
    $ABIO
    $AYI
    $CASA
    $KTRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Building Products
    Consumer Discretionary
    Get the next $ABIO alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.3% on Wednesday.

    The Dow traded up 0.08% to 39,200.08 while the NASDAQ rose 0.46% to 16,315.68. The S&P 500 also rose, gaining, 0.31% to 5,221.70.

    Check This Out: Insiders Buying Walgreens And 2 Other Stocks

     

    Leading and Lagging Sectors

     

    Industrials shares jumped by 0.8% on Wednesday.

    In trading on Wednesday, consumer staples shares fell by 0.9%.

     

    Top Headline

     

    Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings for its second quarter.

    The company posted a quarterly net sales decline of 4.0% year-over-year to $905.9 million, missing the consensus of $907.7 million. It clocked an adjusted EPS of $3.38, beating the consensus of $3.25.

     

    Equities Trading UP

     

    Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares shot up 63% to $0.1637 after the company entered a merger agreement with TuHURA Biosciences.

    Shares of ARCA biopharma, Inc. (NASDAQ:ABIO) got a boost, surging 78% to $3.04 after the company and Oruka Therapeutics announced a merger agreement.

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were also up, gaining 32% to $5.17 after the company's Fanapt received FDA approval for the acute treatment of bipolar I disorder.

     

    Equities Trading DOWN

     

    Casa Systems, Inc. (NASDAQ:CASA) shares dropped 81% to $0.0485 after the Company filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court.

    Shares of View, Inc. (NASDAQ:VIEW) were down 63% to $0.4020 after the company filed for Chapter 11 bankruptcy. The company on Tuesday said it reached a real with Cantor Fitzgerald and RXR to become a private company.

    Sintx Technologies, Inc. (NASDAQ:SINT) was down, falling 46% to $0.0227 after the company announced pricing of a $1.5 million public offering of common stock.

    Also Check This Out: How To Earn $500 A Month From Levi Strauss Stock Ahead Of Q1 Earnings Report

     

    Commodities

     

    In commodity news, oil traded up 0.5% to $85.61 while gold traded up 1.4% at $2,313.90.

    Silver traded up 4.1% to $26.995 on Wednesday, while copper rose 2.9% to $4.1865.

     

    Euro zone

     

    European shares closed higher today. The eurozone’s STOXX 600 rose 0.29%, London’s FTSE 100 rose 0.03% while Spain’s IBEX 35 Index rose 0.52% The German DAX rose 0.46% French CAC 40 rose 0.29% while Italy’s FTSE MIB Index rose 0.45%.

    The consumer price inflation rate in the eurozone eased to 2.4% year-over-year in March, compared to market expectations of 2.6%, while the unemployment rate in the eurozone came in at 6.5% in February, versus market estimates of 6.4%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Wednesday, with Japan’s Nikkei 225 falling 0.97%, Hong Kong’s Hang Seng Index dipping 1.22%, China’s Shanghai Composite Index falling 0.18% and India’s S&P BSE Sensex falling 0.1%.

    Retail sales in Hong Kong climbed 0.5% year-over-year in February following a 1.2% decline in the prior month. The Caixin China General Services PMI rose to 52.7 in March from 52.5 in February, while composite PMI rose to 52.7 in March from 52.5 in the previous two months.

    The au Jibun Bank Japan services PMI fell to 54.1 in March from a preliminary level 54.9, while composite PMI fell to 51.7 in March versus a flash reading of 52.3.

     

    Economics

     

    Mortgage applications in the U.S. declined by 0.6% on the week ending March 29, 2024.

    Private businesses in the U.S. added 184,000 workers in March compared to a revised 155,000 gain in February, and topping market estimates of 148,000.

    The S&P Global composite PMI was revised lower to 52.1 in March from a preliminary reading of 52.2.

    The ISM services PMI declined to 51.4 in March compared to February’s reading of 52.6 and compared to market estimates of 52.7.

    U.S. crude oil inventories increased by 3.21 million barrels in the week ended March 29, 2024, compared to market estimates of a 1.511 million decline, the EIA said.

    Now Read This: Top 5 Industrials Stocks That Could Blast Off This Quarter

    Get the next $ABIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO
    $AYI
    $CASA
    $KTRA

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Acuity Inc.
    $AYI
    10/2/2025$330.00 → $390.00Buy
    TD Cowen
    Acuity Inc.
    $AYI
    9/2/2025$380.00Equal Weight → Overweight
    Wells Fargo
    Acuity Inc.
    $AYI
    1/14/2025$304.00 → $370.00Equal-Weight → Overweight
    Morgan Stanley
    Acuity Inc.
    $AYI
    1/6/2025$304.00Equal-Weight
    Morgan Stanley
    Acuity Inc.
    $AYI
    1/2/2025Mkt Perform → Outperform
    William Blair
    Vanda Pharmaceuticals Inc.
    $VNDA
    10/31/2024$18.00Buy
    H.C. Wainwright
    Vanda Pharmaceuticals Inc.
    $VNDA
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ABIO
    $AYI
    $CASA
    $KTRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $255,350 worth of shares (65,000 units at $3.93) and was granted 53,867 shares, increasing direct ownership by 161% to 192,867 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/8/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $31,900 worth of shares (10,000 units at $3.19), increasing direct ownership by 16% to 74,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    11/10/25 8:00:06 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen reiterated coverage on Acuity with a new price target

    TD Cowen reiterated coverage of Acuity with a rating of Buy and set a new price target of $390.00 from $330.00 previously

    10/2/25 7:48:53 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Acuity upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Acuity from Equal Weight to Overweight and set a new price target of $380.00

    9/2/25 8:18:55 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    $ABIO
    $AYI
    $CASA
    $KTRA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

    SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company's participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and sev

    1/29/26 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Acuity Announces Increase in Quarterly Dividend

    Atlanta, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI) Board of Directors (the "Board") increases the quarterly dividend by 17% percent to 20 cents per share from 17 cents per share. The dividend is payable on February 13, 2026, to shareholders of record on February 2, 2026. About Acuity  Acuity Inc. (NYSE:AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people's lives. We achieve growth throug

    1/22/26 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    $ABIO
    $AYI
    $CASA
    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & Chief Financial Officer Holcom Karen J exercised 897 shares at a strike of $239.76 and sold $1,538,110 worth of shares (4,974 units at $309.23), decreasing direct ownership by 16% to 21,523 units (SEC Form 4)

    4 - ACUITY INC. (DE) (0001144215) (Issuer)

    1/30/26 4:02:35 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    SEC Form 4 filed by Director Sachleben Mark

    4 - ACUITY INC. (DE) (0001144215) (Issuer)

    1/23/26 4:14:28 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    SEC Form 4 filed by Director O'Shaughnessy Laura

    4 - ACUITY INC. (DE) (0001144215) (Issuer)

    1/23/26 4:13:56 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    $ABIO
    $AYI
    $CASA
    $KTRA
    SEC Filings

    View All

    Acuity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ACUITY INC. (DE) (0001144215) (Filer)

    1/23/26 4:16:41 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Vanda Pharmaceuticals Inc.

    SCHEDULE 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    1/9/26 4:23:37 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ACUITY INC. (DE) (0001144215) (Filer)

    1/8/26 7:40:23 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    $ABIO
    $AYI
    $CASA
    $KTRA
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acuity Announces Increase in Quarterly Dividend

    Atlanta, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI) Board of Directors (the "Board") increases the quarterly dividend by 17% percent to 20 cents per share from 17 cents per share. The dividend is payable on February 13, 2026, to shareholders of record on February 2, 2026. About Acuity  Acuity Inc. (NYSE:AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people's lives. We achieve growth throug

    1/22/26 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    Acuity Reports Fiscal 2026 First-Quarter Results

    Delivered Net Sales of $1.1B, an Increase of 20% Compared to the Prior YearDelivered Operating Profit of $160M, Up 20% Compared to the Prior Year; Grew Adjusted Operating Profit to $196M, Up 24% Compared to the Prior YearDelivered Diluted EPS of $3.82, Up 14% Compared to the Prior Year; Grew Adjusted Diluted EPS to $4.69, Up 18% Compared to the Prior Year ATLANTA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI), ("Acuity"), a market-leading industrial technology company, delivered net sales of $1.1 billion in the first quarter of fiscal 2026 ended November 30, 2025, an increase of $192.1 million, or 20.2 percent, compared to the prior year. "We delivered strong performance in ou

    1/8/26 6:00:00 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    $ABIO
    $AYI
    $CASA
    $KTRA
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Acuity Brands Appoints Sach Sankpal to Lead Lighting Business

    ATLANTA, July 30, 2024 (GLOBE NEWSWIRE) -- Acuity Brands, Inc. (NYSE:AYI) ("Acuity"), a market-leading industrial technology company, announced that Sach Sankpal, SVP and Chief Growth and Transformation Officer, has been appointed as President of Acuity Brands Lighting and Lighting Controls ("ABL"). "Since joining Acuity two years ago, Sach has been a positive influence on our performance and our culture," stated Neil Ashe, Chairman, President and CEO of Acuity Brands, Inc. "He brings over 30 years of experience accelerating transformation, driving innovation and positioning global industrial technology organizations for future growth."  Trevor Palmer, the current President of the AB

    7/30/24 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna

    4/25/24 4:15:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acuity Brands Inc.

    SC 13G/A - ACUITY BRANDS INC (0001144215) (Subject)

    11/12/24 9:50:12 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/13/24 4:57:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care